Cargando…
Novel Treatment Strategies Targeting Myelin and Oligodendrocyte Dysfunction in Schizophrenia
Oligodendrocytes are the glial cells responsible for the formation of the myelin sheath around axons. During neurodevelopment, oligodendrocytes undergo maturation and differentiation, and later remyelination in adulthood. Abnormalities in these processes have been associated with behavioral and cogn...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203658/ https://www.ncbi.nlm.nih.gov/pubmed/32425837 http://dx.doi.org/10.3389/fpsyt.2020.00379 |
_version_ | 1783529910216687616 |
---|---|
author | Gouvêa-Junqueira, Danielle Falvella, Ana Caroline Brambilla Antunes, André Saraiva Leão Marcelo Seabra, Gabriela Brandão-Teles, Caroline Martins-de-Souza, Daniel Crunfli, Fernanda |
author_facet | Gouvêa-Junqueira, Danielle Falvella, Ana Caroline Brambilla Antunes, André Saraiva Leão Marcelo Seabra, Gabriela Brandão-Teles, Caroline Martins-de-Souza, Daniel Crunfli, Fernanda |
author_sort | Gouvêa-Junqueira, Danielle |
collection | PubMed |
description | Oligodendrocytes are the glial cells responsible for the formation of the myelin sheath around axons. During neurodevelopment, oligodendrocytes undergo maturation and differentiation, and later remyelination in adulthood. Abnormalities in these processes have been associated with behavioral and cognitive dysfunctions and the development of various mental illnesses like schizophrenia. Several studies have implicated oligodendrocyte dysfunction and myelin abnormalities in the disorder, together with altered expression of myelin-related genes such as Olig2, CNP, and NRG1. However, the molecular mechanisms subjacent of these alterations remain elusive. Schizophrenia is a severe, chronic psychiatric disorder affecting more than 23 million individuals worldwide and its symptoms usually appear at the beginning of adulthood. Currently, the major therapeutic strategy for schizophrenia relies on the use of antipsychotics. Despite their widespread use, the effects of antipsychotics on glial cells, especially oligodendrocytes, remain unclear. Thus, in this review we highlight the current knowledge regarding oligodendrocyte dysfunction in schizophrenia, compiling data from (epi)genetic studies and up-to-date models to investigate the role of oligodendrocytes in the disorder. In addition, we examined potential targets currently investigated for the improvement of schizophrenia symptoms. Research in this area has been investigating potential beneficial compounds, including the D-amino acids D-aspartate and D-serine, that act as NMDA receptor agonists, modulating the glutamatergic signaling; the antioxidant N-acetylcysteine, a precursor in the synthesis of glutathione, protecting against the redox imbalance; as well as lithium, an inhibitor of glycogen synthase kinase 3β (GSK3β) signaling, contributing to oligodendrocyte survival and functioning. In conclusion, there is strong evidence linking oligodendrocyte dysfunction to the development of schizophrenia. Hence, a better understanding of oligodendrocyte differentiation, as well as the effects of antipsychotic medication in these cells, could have potential implications for understanding the development of schizophrenia and finding new targets for drug development. |
format | Online Article Text |
id | pubmed-7203658 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72036582020-05-18 Novel Treatment Strategies Targeting Myelin and Oligodendrocyte Dysfunction in Schizophrenia Gouvêa-Junqueira, Danielle Falvella, Ana Caroline Brambilla Antunes, André Saraiva Leão Marcelo Seabra, Gabriela Brandão-Teles, Caroline Martins-de-Souza, Daniel Crunfli, Fernanda Front Psychiatry Psychiatry Oligodendrocytes are the glial cells responsible for the formation of the myelin sheath around axons. During neurodevelopment, oligodendrocytes undergo maturation and differentiation, and later remyelination in adulthood. Abnormalities in these processes have been associated with behavioral and cognitive dysfunctions and the development of various mental illnesses like schizophrenia. Several studies have implicated oligodendrocyte dysfunction and myelin abnormalities in the disorder, together with altered expression of myelin-related genes such as Olig2, CNP, and NRG1. However, the molecular mechanisms subjacent of these alterations remain elusive. Schizophrenia is a severe, chronic psychiatric disorder affecting more than 23 million individuals worldwide and its symptoms usually appear at the beginning of adulthood. Currently, the major therapeutic strategy for schizophrenia relies on the use of antipsychotics. Despite their widespread use, the effects of antipsychotics on glial cells, especially oligodendrocytes, remain unclear. Thus, in this review we highlight the current knowledge regarding oligodendrocyte dysfunction in schizophrenia, compiling data from (epi)genetic studies and up-to-date models to investigate the role of oligodendrocytes in the disorder. In addition, we examined potential targets currently investigated for the improvement of schizophrenia symptoms. Research in this area has been investigating potential beneficial compounds, including the D-amino acids D-aspartate and D-serine, that act as NMDA receptor agonists, modulating the glutamatergic signaling; the antioxidant N-acetylcysteine, a precursor in the synthesis of glutathione, protecting against the redox imbalance; as well as lithium, an inhibitor of glycogen synthase kinase 3β (GSK3β) signaling, contributing to oligodendrocyte survival and functioning. In conclusion, there is strong evidence linking oligodendrocyte dysfunction to the development of schizophrenia. Hence, a better understanding of oligodendrocyte differentiation, as well as the effects of antipsychotic medication in these cells, could have potential implications for understanding the development of schizophrenia and finding new targets for drug development. Frontiers Media S.A. 2020-04-30 /pmc/articles/PMC7203658/ /pubmed/32425837 http://dx.doi.org/10.3389/fpsyt.2020.00379 Text en Copyright © 2020 Gouvêa-Junqueira, Falvella, Antunes, Seabra, Brandão-Teles, Martins-de-Souza and Crunfli http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Gouvêa-Junqueira, Danielle Falvella, Ana Caroline Brambilla Antunes, André Saraiva Leão Marcelo Seabra, Gabriela Brandão-Teles, Caroline Martins-de-Souza, Daniel Crunfli, Fernanda Novel Treatment Strategies Targeting Myelin and Oligodendrocyte Dysfunction in Schizophrenia |
title | Novel Treatment Strategies Targeting Myelin and Oligodendrocyte Dysfunction in Schizophrenia |
title_full | Novel Treatment Strategies Targeting Myelin and Oligodendrocyte Dysfunction in Schizophrenia |
title_fullStr | Novel Treatment Strategies Targeting Myelin and Oligodendrocyte Dysfunction in Schizophrenia |
title_full_unstemmed | Novel Treatment Strategies Targeting Myelin and Oligodendrocyte Dysfunction in Schizophrenia |
title_short | Novel Treatment Strategies Targeting Myelin and Oligodendrocyte Dysfunction in Schizophrenia |
title_sort | novel treatment strategies targeting myelin and oligodendrocyte dysfunction in schizophrenia |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203658/ https://www.ncbi.nlm.nih.gov/pubmed/32425837 http://dx.doi.org/10.3389/fpsyt.2020.00379 |
work_keys_str_mv | AT gouveajunqueiradanielle noveltreatmentstrategiestargetingmyelinandoligodendrocytedysfunctioninschizophrenia AT falvellaanacarolinebrambilla noveltreatmentstrategiestargetingmyelinandoligodendrocytedysfunctioninschizophrenia AT antunesandresaraivaleaomarcelo noveltreatmentstrategiestargetingmyelinandoligodendrocytedysfunctioninschizophrenia AT seabragabriela noveltreatmentstrategiestargetingmyelinandoligodendrocytedysfunctioninschizophrenia AT brandaotelescaroline noveltreatmentstrategiestargetingmyelinandoligodendrocytedysfunctioninschizophrenia AT martinsdesouzadaniel noveltreatmentstrategiestargetingmyelinandoligodendrocytedysfunctioninschizophrenia AT crunflifernanda noveltreatmentstrategiestargetingmyelinandoligodendrocytedysfunctioninschizophrenia |